Description: Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Home Page: www.blackdiamondtherapeutics.com
BDTX Technical Analysis
One Main Street
Cambridge,
MA
02142
United States
Phone:
617 252 0848
Officers
| Name | Title |
|---|---|
| Dr. David M. Epstein Ph.D. | Co-Founder, Pres, CEO & Director |
| Dr. Fang Ni Pharm.D. | CFO, Principal Financial Officer and Chief Bus. Officer |
| Mr. Brent Hatzis-Schoch Esq., J.D. | COO & Gen. Counsel |
| Dr. Elizabeth Buck Ph.D. | Co-Founder & Chief Scientific Officer |
| Ms. Erika Jones | VP of Fin., Corp. Controller & Principal Accounting Officer |
| Ms. Elizabeth L. Montgomery | Chief People Officer |
| Dr. Christopher D. Roberts Ph.D. | Advisor |
| Mr. Tai-An Lin Ph.D. | Sr. VP of Translational Science & Discovery Biology |
| Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer |
| Ms. Melanie Morrison | Sr. VP of Devel. Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.404 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-01-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 86 |